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The immune response to acute cerebral ischemia is a major contributor to stroke
pathobiology. The inflammatory response is characterized by the participation of brain
resident cells and peripheral leukocytes. Microglia in the brain and monocytes/neutrophils
in the periphery have a prominent role in initiating, sustaining and resolving post-ischemic
inflammation. In this review we aim to summarize recent literature concerning the origins,
fate and role of microglia, monocytes and neutrophils in models of cerebral ischemia and
to discuss their relevance for human stroke.
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INTRODUCTION
Cerebral ischemia triggers a robust activation of brain resident
and peripheral immune cells, which play an active role in the
acute and chronic phases of injury, as well as in subsequent
reorganization and repair processes (Iadecola and Anrather,
2011; Macrez et al., 2011; Shichita et al., 2012). Numerous
experimental studies have depicted the pivotal response of
resident microglia, infiltrating monocyte-derived macrophages
and neutrophils to either the development of the brain injury
or its resolution leading to conflicting interpretation of their
protective or deleterious contribution in stroke (Emerich et al.,
2002; Chiba and Umegaki, 2013), and ultimately to treat-
ment failure (O’Collins et al., 2006; Smith et al., 2013). Fur-
thermore, discrepancies exist towards the provenance of brain
macrophages, that is to say whether they are blood-borne
monocytes or resident microglia that further differentiate into
macrophages (London et al., 2013). A better understanding
of the origin and function of myeloid immune cells pop-
ulating the ischemic brain may provide the opportunity to
manipulate specific subsets for therapeutic benefit. The aims
of this review are (a) to summarize the origin and develop-
ment of leukocytes and resident microglia, (b) to delineate
their contribution to ischemic injury based on recent litera-
ture, and (c) to assess their therapeutic relevance to human
stroke.
ORIGIN AND DEVELOPMENT OF NEUTROPHILS,
MONOCYTES AND MICROGLIA
Cerebral ischemia induces a time-dependent recruitment and
activation of leukocytes including neutrophils, monocytes and
lymphocytes (Iadecola and Anrather, 2011). At the site of injury,
macrophage populations consist mainly of activated parenchymal
microglia and infiltrating peripheral monocytes that have distinct
ontogenesis (London et al., 2013; Prinz and Priller, 2014). Once in
the injured tissue, both cell types differentiate into macrophages
and may be indistinguishable by classical histological methods
since they share similar antigens and morphologies (Prinz and
Mildner, 2011). In the next sections, we will summarize recent
findings on the origin, fate and function of myeloid immune
cells and microglia particularly in the context of acute cerebral
ischemia.
ORIGIN AND FATE OF NEUTROPHILS
Neutrophils are innate immune cells and are the first line of
defense against microbial infectious agents. They are involved in
the phagocytosis, killing and degrading of microorganisms, partly
through the generation of reactive oxygen and nitrogen species
(ROS/RNS). Neutrophils are generated in the bone marrow (BM)
and share with monocytes the common progenitor granulocyte
macrophage precursor (GMP; Figure 1). Only mature neutrophils
are normally released from the BM into circulation, where they
exist as circulating and marginated neutrophil pools, primarily
in the lung, which can be acutely mobilized for example by
adrenergic agonists (Bierman et al., 1951, 1952). After termi-
nal differentiation, under homeostatic conditions, neutrophils
remain in the BM for additional 4–6 days before being released
into circulation, constituting a BM neutrophil reserve (Craddock
et al., 1960). Egress is controlled by the antagonistic activities of C-
X-C chemokine receptor type 2 (CXCR2) and CXCR4 receptors.
Activation of CXCR2, which binds C-X-C ligand 1 (CXCL1)
and CXCL2 chemokines, stimulates BM egress, whereas stromal
cell derived CXCL12 (SDF-1) acting on CXCR4 favors reten-
tion (Strydom and Rankin, 2013). During neutrophil maturation
CXCR2 expression increases, while CXCR4 is downregulated,
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FIGURE 1 | Origin and trafficking of resident microglia and immune cells
of myeloid origin. Fetal liver and spleen/bone marrow panel: Monocytes are
generated from hematopoietic stem cells (HSCs) in the fetal liver and during
adult life in the bone marrow (BM). The granulocyte macrophage precursors
(GMP) give rise to immature neutrophils and the macrophage dendritic cell
precursors (MDPs). Monocytes develop from hematopoietic stem cells (HSC)
after myeloid lineage commitment through a series of increasingly restricted
progenitors (GMP, granulocyte/monocyte progenitor; MDP,
monocyte/dendritic cell progenitors). The common monocyte progenitor
(CMP) is the direct precursors of mature Ly6Chigh and Ly6Clow monocytes.
Ly6Chigh inflammatory monocytes might give rise to circulating Ly6Clow
monocytes directly, or via a Ly6Chigh monocyte intermediate. Yolk sac panel:
Resident brain microglia have been shown recently to have a different origin
than circulating monocytes. During embryonic life, erythroblasts (not shown)
and macrophage progenitors are generated in the yolk sac from the common
erythro-myeloid progenitor. When the blood circulation is established,
macrophage precursors exit the yolk sac and migrate into the developing
brain. Embryonic microglia proliferate and are able to renew themselves
during gestation and post-natal development as well as in adulthood. Blood
vessel and Ischemic brain panels: Few hours after cerebral ischemia onset,
mature neutrophils enter the bloodstream upon activation of the CXCR2
receptor and infiltrate the brain in response to chemokines CKLF1 as well as
CXCL1 and CXCL2 released by astrocytes. Astrocytic production of these
chemokines is dependent upon IL-17 released from brain infiltrating γδT cells.
Neutrophils firmly adhere to the endothelium and might either invade the
ischemic region or cluster into the perivascular space. During injury, CCL2 is
produced by astrocytes, macrophages/microglia and neurons. CCL2 binds its
receptor CCR2 expressed by Ly6Chigh inflammatory monocytes, which
promotes their egress from the BM into the blood, and then their recruitment
from the blood into the injured tissue. Here, these cells give rise to
monocyte-derived DC (not shown) and monocyte-derived macrophage
populations, which can further polarize into M1 and M2 macrophages. As the
ischemic infarct develops, M1 and M2 macrophages contribute to the
exacerbation of the damage or wound healing, respectively. Ly6Clow
monocytes patrol the blood vessel lumen by associating with the vascular
endothelium. Ly6Clow monocytes expressing the CX3CR1 receptor are also
recruited to sites of inflammation and possibly contribute to wound healing by
differentiating into alternatively activated M2 macrophages. Cerebral
ischemia/reperfusion leads to the release of damage-associated molecular
pattern (DAMP) molecules from dying neurons. These molecules trigger the
activation of resident microglia and astrocytes. Activated microglia promote
tissue repair by producing trophic factors and by scavenging necrotic cells.
Regulatory T lymphocytes (Treg) secreting IL-10 have shown a protective role
in cerebral ischemia and might promote macrophage M2 polarization. Spleen
panel: An interesting twist to the origin of recruited monocytes during injury
has been added by the recent identification of a major monocyte reservoir in
the spleen of mice. Following ischemic myocardial injury, splenic monocytes
are mobilized to the site of inflammation and participate in tissue injury
(Swirski et al., 2009). Dashed arrows represent findings that are not clearly
defined yet and need further investigations in context of cerebral ischemia.
which eventually leads to neutrophils egress from the BM. Once
in the circulation, neutrophils are thought to be one of the
most short-lived cells in the body with circulating half-life of
roughly 8 h in humans and 13 h in mice (von Vietinghoff and
Ley, 2008; Bugl et al., 2012). As the neutrophil age, CXCR4
receptors become upregulated favoring homing to spleen, liver
and BM, wherein neutrophils die by apoptosis and are cleared by
resident macrophages. In inflammation, extravasated neutrophils
show increased life span of several days and might die as a
result of their own cytotoxic molecules by necrosis and by releas-
ing cytotoxic neutrophil extracellular traps (NETs; Yipp et al.,
2012).
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MONOCYTES, THE BLOOD-BORNE PRECURSORS OF INDUCED TISSUE
MACROPHAGES
Similar to neutrophils, monocytes are generated from definitive
hematopoietic stem cells (HSC) in the liver and spleen during
embryonic development and primarily in the BM after birth
(Auffray et al., 2009; Ginhoux and Jung, 2014; Figure 1). After
lineage commitment they proceed through increasingly more
restricted progenitor stages to give rise to mature monocytes
that are released into circulation after engagement of the C-C
chemokine receptor type 2 (CCR2; Tsou et al., 2007; Hettinger
et al., 2013). In the circulation, they can be distinguished
from other leukocytes by their myeloid nature, as indicated by
(a) high-level expression of CD11b/Mac-1 (a member of the
α-integrin family of proteins) and CD115 (colony simulating
factor 1 receptor, CSF1R), (b) their phagocytic capacity and
(c) their ability to develop into macrophages upon stimulation
with CSF-1 in vitro (Chitu and Stanley, 2006). There is sub-
stantial heterogeneity in circulating monocytes and they can
be further divided into functionally distinct subsets according
to their surface expression of lymphocyte antigen 6 complex,
locus C1 (Ly6C; Swirski et al., 2007; Geissmann et al., 2008),
the CCR2 receptor (Geissmann et al., 2003; Prinz and Priller,
2010) and CX3CR1—the high-affinity functional chemokine
receptor for fractalkine (Imai et al., 1997). CD115+/Ly6Chigh
monocytes that express CCR2 are termed “inflammatory” mono-
cytes because they are highly mobile and selectively recruited
to inflamed tissues (Auffray et al., 2007; Swirski et al., 2010;
Terry et al., 2012). In contrast, CD115+/Ly6Clow monocytes
that express CX3CR1 and are negative for CCR2 were initially
termed “resident” monocytes because of their longer half-life
in circulation and their accumulation in tissues under homeo-
static conditions (Geissmann et al., 2003). This subset has been
later termed “patrolling” monocytes because of their crawling
behavior along the vascular endothelium, and has been shown
to orchestrate the disposal of dying or infected endothelial
cells (Auffray et al., 2007; Carlin et al., 2013). Their accumu-
lation in the tissue is facilitated by the expression of CX3CR1
that mediates their adhesion and migration (Geissmann et al.,
2003). Several reports have proposed that “patrolling” mono-
cytes originate from CD115+/Ly6Chigh monocytes in the cir-
culation (Sunderkötter et al., 2004; Lin et al., 2009). However,
recent data suggest that Ly6Clow monocytes are generated from
a myeloid progenitor by the activity of the transcription factor
NR4A1 (Nur77) in the BM (Hanna et al., 2011). Additionally,
depletion of CD115+/Ly6Chigh monocytes in the blood does
not affect the numbers of circulating CD115+/Ly6Clow mono-
cytes making it unlikely that CD115+/Ly6Chigh cells are the only
precursors of “patrolling” monocytes (Geissmann et al., 2008;
Figure 1).
Under physiological conditions, most CD115+/Ly6Clow crawl-
ing monocytes are found within the blood vessels and extrava-
sation rarely occurs. However, in response to tissue damage or
infection, these cells extravasate faster than CD115+/Ly6Chigh
monocytes and are the main TNF producers in the early phase
of the inflammatory response (Auffray et al., 2007). In contrast,
in a model of myocardial infarction Ly6Chigh monocytes are the
first population to be present in the injured myocardium and
display proteolytic and inflammatory functions consistent with a
role in tissue damage. Ly6Clow monocytes are the predominant
population during the resolution phase of the inflammatory
response and express repair-promoting proteins such as vascular
endothelial growth factor (VEGF; Nahrendorf et al., 2007). The
accumulation of Ly6Chigh and Ly6Clow monocytes in inflamed
tissues occurs in two phases, although the sequence of infiltra-
tion by specific monocyte subsets differs between models, e.g.,
bacterial infection vs. sterile inflammation (Auffray et al., 2007;
Nahrendorf et al., 2007). Thus, Ly6Chigh and Ly6Clow monocytes
can have pro- or anti-inflammatory functions depending on the
nature of the inflammatory stimulus, the tissue microenviron-
ment and their molecular profile (transcription factors, gene
expression, etc.).
MICROGLIA, THE RESIDENT BRAIN MACROPHAGES
In contrast to monocytes, microglia originate exclusively from
the yolk sac and colonize the central nervous system (CNS)
early during embryonic development before E9 (Ginhoux et al.,
2010, 2013; Schulz et al., 2012; Frame et al., 2013). There,
yolk sac-derived macrophages proliferate and give rise to mature
microglia (Figure 1). It seems that microglia are long-lived under
physiological conditions and are not normally replaced by BM-
derived cells (Alliot et al., 1999; Ajami et al., 2007; Kierdorf
et al., 2013a). Recent evidence indicates that microglia home-
ostasis in adult mice is highly dependent on continuous pro-
survival signals provided by the CSF-1 receptor CD115 (Elmore
et al., 2014). Blockage of the receptor by selective inhibitors
for as little as 7 days resulted in nearly complete depletion of
brain microglia. Fast recovery of the microglia population was
observed after withdraw of the blocker due to proliferation of
brain resident progenitors. These progenitors expressed the neu-
roectodermal marker Nestin, the hematopoietic marker CD45,
the stem cell marker CD34 and stained positive for isolectin B4
(IB4) while being negative for myeloid markers such as ionized
calcium binding adapter molecule (Iba1; Elmore et al., 2014).
While this is the first study to identify brain-resident microglial
progenitors, microglia expansion has been previously described
in several disease models. In a model of amyotrophic lateral
sclerosis, Solomon et al. characterized the temporal and spatial
infiltration of green fluorescent protein (GFP)-BM cells trans-
planted into lethally irradiated mice. The increased number of
spinal cord macrophages following disease onset was attributed
to the expansion of resident microglia rather than infiltrated BM-
derived precursors (Solomon et al., 2006). Similarly, in experi-
mental autoimmune encephalitis (EAE), Ajami et al. found that
blood-borne monocytes transiently infiltrate the spinal cord but
do not contribute to the long-term pool of resident microglia
(Ajami et al., 2011). Techniques such as parabiosis (Ajami et al.,
2007; Ransohoff, 2011), whole body irradiation, head-shielded
BM chimeras (Mildner et al., 2011), transgenic mice (Saederup
et al., 2010) and fate mapping analysis (Ginhoux et al., 2010)
have been instrumental to better discriminate between infiltrat-
ing myeloid immune cells and resident microglia. Furthermore,
recent data indicate that microglia express a distinctive genetic
signature that makes them distinguishable from neurons, astro-
cytes, oligodendrocytes, and peripheral immune cells including
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other tissue macrophages. Using transcriptomic and proteomic
analysis Butovsky et al. identified several genes that were specif-
ically expressed in CD11b+/CD45low microglia when compared
to blood monocytes (Butovsky et al., 2014). Among them, the
purinergic receptor P2ry12, the proto-oncogene tyrosine kinase
Mertk, and the Fc receptor-like S scavenger receptor Fcrls were
exclusively expressed in microglia in brain and spinal cord, and
not in peripheral tissue macrophages, e.g., Kupfer cells, alveolar
macrophages, etc. P2ry12, Mertk and Fcrls are surface expressed
proteins enabling easy antibody-mediated detection in flow cyto-
metric and histological assays. Given that this genetic signature
is similar between mice and human microglia, a better differ-
entiation of infiltrating myeloid cells and microglia in human
stroke should also be possible. In a model of EAE, expression
of these genes was restricted to microglia and was not found in
infiltrated monocytes (Butovsky et al., 2014). However, because
the analysis was conducted at disease onset, it is not clear whether
the signature is retained as the pathology progresses. It remains
to be determined whether expression of these marker genes is
preserved during all stages of microglial activation, as observed
in cerebral ischemia, or whether a similar molecular signature
can be acquired by infiltrating monocytes that develop into
tissue macrophages. For example, monocytes entering the brain
parenchyma could be exposed to a brain-specific environment
favoring expression of a microglia-like phenotype. Therefore, a
better knowledge of unique genetic signatures and reliable cellular
markers would greatly facilitate studies of the origin, function and
fate of inflammatory cells in ischemic brain injury.
POLARIZATION OF MONOCYTES- AND MICROGLIA-DERIVED
MACROPHAGES
Once in the damaged tissue, CD115+ peripheral-blood mono-
cytes have the ability to differentiate into macrophages and further
polarize into several subtypes with specific functions including
production of inflammatory molecules and phagocytic activity.
Macrophage polarization depends on the type of injury, the
nature of the pathogen, the organs involved and interactions
with other immune cells. The distinct phenotypes and physio-
logical activities associated with tissue macrophages were mostly
described in vitro and in non-neuronal tissue, and have only
recently been examined in the context of cerebral ischemia.
“Classically activated macrophages” or “M1 macrophages” have
anti-microbial activity and secrete pro-inflammatory cytokines
and reactive oxygen species upon stimulation with interferon-γ
(IFNγ) and lipopolysaccharide (LPS; Mills et al., 2000; Gordon
and Taylor, 2005; Mosser and Edwards, 2008). On the other
hand, “alternative” or M2 macrophages, induced by interleukin-4
(IL-4), IL-10 or transforming growth factor-β (TGF-β), promote
anti-inflammatory and reparative processes (Mantovani et al.,
2004; Hao et al., 2012; Yang et al., 2014). Several differentially
regulated genes have been associated with each polarization state
and are used to distinguish between these two populations in
mice, including the IgG Fc receptors CD16/32 and inducible
nitric oxide synthase (iNOS) for the M1 phenotype, and mannose
receptor (CD206), arginase 1 (Arg1), chitinase-like 3 (Chil3 or
Ym1), and IL-10 for the M2 phenotype (Table 1; Hu et al., 2012;
Liu et al., 2013; Murray et al., 2014; Tang et al., 2014).
It must be noted that M1 and M2 are the extreme phenotypes
of the broad and heterogeneous activation states of macrophages,
and caution is needed in interpreting their multivalent function
under pathological conditions (Murray et al., 2014). Recently,
the M1/M2 terminology was also applied to activated microglia
(Michelucci et al., 2009; David and Kroner, 2011). Exposure of
cultured primary microglia to LPS or IFNγ induces a M1-like
phenotype with reduced phagocytic activity and expression of
iNOS, TNF, IL-1β and IL-6 among others, while IL-4 drives
microglia towards a M2-like phenotype with increased Arg1,
Ym1 and resistin like α (RELMα, FIZZ1) expression (Michelucci
et al., 2009). Others have compared capacity of microglia and
blood- or BM-derived macrophages to assume M1 or M2 phe-
notypes using in vitro polarization protocols (Durafourt et al.,
2012; Girard et al., 2013). These authors assessed morphol-
ogy, surface markers, cytokine profile and phagocytic capac-
ity of both polarized blood-borne macrophages and microglia
(Durafourt et al., 2012) or compared expression levels of M1/M2
marker genes (Girard et al., 2013). Girard et al. found that both
mouse BM-derived macrophages and BV2 microglial cell line
displayed a M1 or M2 phenotypes after LPS or IL-4 stimulation,
respectively. In contrast, Durafourt et al. found that human
microglia was able to respond to both M1 and M2-inducing
stimuli, but their M2 gene expression signature was restricted
to CD209 and the expression of CD23, CD163, and CD206
was not increased, as observed in M2 polarized macrophages
(Durafourt et al., 2012). Although the functional implications
remain to be established, these observations highlight important
differences between human and mouse microglia. Interestingly,
adult human microglia showed higher phagocytic activity and
IL-10 expression than macrophages under M1 and M2 condi-
tions, indicating that even in a pro-inflammatory environment
microglia can retain anti-inflammatory function, which might
be essential for their neuroprotective activity (Durafourt et al.,
2012).
CONTRIBUTION OF IMMUNE CELLS OF MYELOID ORIGIN
AND MICROGLIA TO CEREBRAL ISCHEMIC INJURY
Acute cerebral ischemia leads to rapid neuronal cell death and
activation of resident microglia as well as the infiltration of
blood-borne immune cells (Gelderblom et al., 2009; Dénes et al.,
2010; Figure 2). Activated microglia become phagocytic aiming
to clear the damage and promote repair (Faustino et al., 2011).
If blood flow is not rapidly restored and ischemic damage devel-
ops, injured neurons release damage-associated molecular pattern
proteins leading to the secretion of pro-inflammatory media-
tors and formation of ROS from parenchymal cells (del Zoppo
et al., 2000; Shichita et al., 2012; Jackman and Iadecola, 2014).
Cytokines and ROS, produced both in the vascular and parenchy-
mal compartments, induce the disruption of the blood brain bar-
rier (BBB) facilitating the infiltration of circulating monocytes,
neutrophils and lymphocytes, thereby promoting post-ischemic
inflammation (Iadecola and Anrather, 2011; Kleinschnitz et al.,
2013; García-Bonilla et al., 2014b). However, neutrophils, as well
as monocytes, some T- and B-cells and microglia may also exhibit
anti-inflammatory properties that are important for limiting neu-
ronal injury, resolving the inflammation and promoting tissue
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Table 1 | Different activation states of neutrophils, circulating monocytes and tissue macrophages in mice.
Neutrophils Circulating monocytes Monocyte-derived macrophages Resident microglia
Subsets N1/N2 “Inflammatory” “Patrolling” M1 M2 Surveying Microglia-derived
monocytes monocytes (M2a,b,c) microglia macrophages
Marker iNOS iNOS Arg1, CD206, DAP12
genes Chil3 (Ym1)
Receptor CD45high CD45high CD45high CD45high CD45high CD45int CD45high
expression CD11b+ Ly6Chigh Ly6Clow CD115+ CD115+ CD11b+ CD11b+
Ly6G+ CD115+ CD115+ CD11b+ CD11b+ CX3CR1 CD115+
CCR2+ CCR2− F4/80+ F4/80+ Ibal+ F4/80+
CX3CR1int CX3CR1+ CD68 (ED-1) CD68 (ED-1) IB4 CD68 (ED-1)
Ly6G- Ly6G- CCR2+ CX3CR1+ CX3CR1+
Iba1+ IB4
Activated Platelets, Neutrophils, Th1, NK Th2 Neurons Dying
by [cells] Endothelial cells Dying neurons neurons
Activated by IL-1α CCL2 LPS, IFNγ, IL- 4 and IL-13 (M2a), DAMPs,
[molecules] TNF IL-10, Glucocorticoid, CX3CL1
TGFβ (M2c),
CCL2 (MCP1)
Function Neurotoxic Recruited at sites Endothelium Cytotoxic Phagocytic Synaptic pruning Phagocytosis,
(N1), of inflammation, integrity effect capacity, and remodeling Neurotoxicity
Neuroprotection Precursors of Promote during
(N2) peripheral neurite development,
mononuclear outgrowth Homeostatic
phagocytes functions
Cell ROS, NO, TNF, ROS, IL-10, IL-12, IL-23, TGFβ, Arg1 TGFβ IL-1β,
products RNS, NO, IL-1β, VEGF TNF, IL-1β, and scavenger TNF, IL-6,
MMP-9, Little IL-10 IL-6, ROS receptors (M2a), Chemokines,
NE IL-10 (M2c). IFNγ
The dichotomy in the function of each cell type shown here is an oversimplified view of their activation state. They rather undergo multiple activation phenotypes at
a given time making the interpretation of their neuroprotective or/and deleterious effect in cerebral ischemia complex. Whether N1/N2 and M1/M2 phenotypes may
apply to neutrophils and microglia, respectively, would need further investigation.
Abbreviations: Arginase 1 (Arg1), Chemokine (C-C motif) ligand 2 (CCL2), C-C chemokine receptor type 2 (CCR2), Chitinase-like 3 (Chil3 or Ym1), CX3C chemokine
receptor 1 (CX3CR1), Damage-associated molecular pattern molecules (DAMPs), DNAX activation protein of 12 kDa (DAP12), inducible nitric oxide synthase
(iNOS), Interferon gamma (IFNγ), Interleukin-1,4,6,10,12,23 (IL-1, IL-4, IL-6, IL-10, IL-12, IL-23), Ionized calcium binding adaptor molecule 1 (Iba1), Isolectin B4
(IB4), Lipopolysaccharide (LPS), Lymphocyte antigen 6G (Ly6G), Matrix metallopeptidase 9 (MMP-9), monocyte chemotactic protein 1 (MCP1), Natural Killer (NK),
Neutrophil elastase (NE), Nitric oxide (NO), Reactive nitrogen species (RNS), Reactive oxygen species (ROS), Transforming growth factor beta (TGF-β), Tumor necrosis
factor (TNF), Type 1 T helper (Th1), Type 2 T helper (Th2), Vascular Endothelial Growth Factor (VEGF).
repair (Liesz et al., 2009; Yilmaz and Granger, 2010; Bodhankar
et al., 2014). Characterizing the dynamics of leukocyte infiltration
after cerebral ischemia is important to understand their func-
tional role and therapeutic potential. Notably, the magnitude and
temporal profile of peripheral immune cell infiltration depends
upon models of focal cerebral ischemia. For example, permanent
ischemia leads to immune cell infiltration as early as 3 h and
a more pronounced accumulation of neutrophils compared to
transient ischemia (Zhou et al., 2013; Chu et al., 2014b), wherein
blood-borne immune cells do not appear in large numbers until
48 h after reperfusion (Stevens et al., 2002; Gelderblom et al.,
2009; García-Bonilla et al., 2014b). These differences in the timing
of cellular infiltration relative to the development of tissue injury
hint at different roles of blood-borne immune cells in these two
stroke models. These considerations need to be taken into account
when extrapolating findings obtained in animal models to human
stroke for therapeutic purposes.
NEUTROPHILS IN BRAIN ISCHEMIA
Neutrophils respond to sterile inflammation, such that induced
by brain ischemia, by interacting with endothelial adhesion
molecules, mainly selectin family members and intracellular
adhesion molecule-1 (ICAM-1), to slow their intravascular move-
ment and induce polarization, which results in firm adhesion
to the pro-inflammatory endothelium (Panés et al., 1995, 1999).
Rolling and adhesion of leukocytes can be observed in vivo as
early as 1 h after transient middle cerebral artery (MCA) occlusion
and is characterized by neutrophil attachment to the endothe-
lium and increased platelet-neutrophil interactions which is P-
selectin and integrin αIIbβ3 dependent (Ishikawa et al., 2004).
Due to the proximity of platelets and neutrophils, IL-1α released
from activated platelets, might be an early activator of neutrophils
(Thornton et al., 2010).
After initial adherence, neutrophils will follow a chemokine
and activator gradient produced by the injured tissue. Neutrophils
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FIGURE 2 | Spatiotemporal profile of myeloid immune cell
activation in acute cerebral ischemia. Schematic representation of
rodent brain coronal sections through the anterior commissure
(bregma = 0) after transient MCA occlusion in C57BL/6 mice. The core
of the infarct is represented in red and the peri-infarct area is shown in
light red. The evolution of the infarct is based on observations of ours
and others and depicted as follow: infarct size becomes detectable
1 day after transient MCA occlusion, is maximal at 3–5 days after
ischemia onset and decreases afterwards together with shrinkage of
the injured hemisphere and enlargement of the ventricles. Before injury,
resident microglia display ramified thin processes and are highly motile.
They scan their microenvironment to detect any disturbances. Cerebral
ischemia triggers microglia to become activated and to display distinct
shapes and expression patterns upon the course of reperfusion. Based
on findings depicted here, microglia become activated at the onset of
cerebral ischemia—as early as 1 day after injury—and further develop
into macrophages. In the core of the infarct, microglia are round-shaped,
expressed ED-1 and display a M2 phenotype aimed at phagocytize the
cellular debris and clear the damaged tissue. In the peri-infarct region
microglia have ramified processes but are negative for the phagocytic
marker ED-1. They are present early after injury, peak between 5–7 days
and decrease thereafter. Neutrophils are the first myeloid immune cells
to invade the brain and might display a N1 or N2 phenotypes. They can
be detected in the ischemic region from 1 to 5–7 days after injury.
Monocytes infiltrate the ischemic parenchyma after microglia activation
and transform into macrophages. Between 3–5 days M2 macrophages
are more abundant in the striatum—the core of the infarct—and decline
by 2 weeks. In contrast, pro-inflammatory M1 cells are first observed in
the peri-infarct of the lesion and increase in number in the core over
time and outnumber the M2 macrophages later on. From 3–5 days
onwards it is not clear yet whether the so called M1 and M2
macrophages found in the ischemic region are derived preferentially
from microglia or infiltrated monocytes and if they have similar
functions. Preliminary data suggest that microglia-derived macrophages
can proliferate and have greater phagocytic properties than
monocytes-derived macrophages.
are the first blood-borne cells found in the ischemic area,
reach peak numbers at days 2–4 after transient ischemia
and decline thereafter (Gelderblom et al., 2009; García-
Bonilla et al., 2014b). The CXCR2 ligands CXCL1 (KC)
and CXCL2 (MIP-2α) are the main chemokines responsible
for neutrophil extravasation. In the ischemic brain CXCL1
is produced by activated astrocytes in an IL-17 dependent
manner (Figure 1; Gelderblom et al., 2012). Chemokine-like
factor 1 (CKLF1), a recently discovered chemokine, partici-
pates in neutrophil recruitment after transient focal ischemia
in rats and anti-CKLF1 antibodies diminished neuronal cell
death in this model (Kong et al., 2014). The sequence of
molecular events regulating neutrophil extravasation remains
incompletely understood. CD47, a immunoglobulin superfamily
transmembrane glycoprotein expressed on the cell surface of
neutrophils, is essential for neutrophil transmigration in vivo
and in vitro (Liu et al., 2001; Su et al., 2008). Accordingly,
CD47 deficient mice exhibit reduced brain injury and neu-
trophil infiltration after transient focal ischemia (Jin et al.,
2009).
Endothelial transmigration seems to be essential for the
cytotoxic activation of neutrophils (Allen et al., 2012), which
is accomplished by induction of ROS production by NADPH
oxidase and myeloperoxidase, iNOS dependent nitric oxide gen-
eration and concomitant release of RNS, particularly peroxyni-
trite (Yilmaz and Granger, 2010). Work from our group has
shown that iNOS expression in endothelial cells and neutrophils
contributes to ischemic brain injury after transient MCA occlu-
sion, but was dispensable for neutrophil recruitment (Iadecola
et al., 1997; García-Bonilla et al., 2014a). On the other hand,
adoptive transfer of iNOS+/+ neutrophils into an iNOS−/− host
24 h after MCA occlusion was sufficient to revert the protection
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exerted by iNOS deletion (García-Bonilla et al., 2014a). Other
potentially neurotoxic molecules released by neutrophils are
extracellular proteases. Among them, matrix metalloproteinase
9 (MMP-9), a protease released during neutrophil degranula-
tion, has been shown to contribute to ischemic injury (Romanic
et al., 1998). Neutrophil elastase (NE), has also been impli-
cated in brain injury after transient but not permanent focal
ischemia (Shimakura et al., 2000; Stowe et al., 2009). There
is still debate to what extent neutrophils contribute to post-
ischemic inflammation and neuronal cell death. While neu-
trophil depletion by delivery of anti-neutrophil antibodies was
neuroprotective in focal ischemia models (Matsuo et al., 1994),
several approaches to limit neutrophil infiltration by cytotoxic
drugs or adhesion molecule and chemokine receptor block-
ade have been unsuccessful (Soriano et al., 1999; Beray-Berthat
et al., 2003b; Brait et al., 2011), or have suggested that the
contribution of neutrophils to ischemic injury might be brain
region specific (Beray-Berthat et al., 2003a). It has also been
suggested that neutrophils do not penetrate the ischemic brain
tissue but accumulate in the perivascular space after extrava-
sation (Enzmann et al., 2013). However, this finding does not
exclude their participation in ischemic injury since neutrophils
would be still able release soluble cytotoxic molecules such as
ROS, RNS, and proteases, which could induce vascular damage
aggravating the ischemia or diffuse into the brain parenchyma
causing tissue injury. Indeed, our iNOS BM chimera and adop-
tive transfer experiments (García-Bonilla et al., 2014b), collec-
tively, support a deleterious role of neutrophils in ischemic brain
injury.
FUNCTIONAL POLARIZATION OF NEUTROPHILS IN CEREBRAL
ISCHEMIA
In addition to their deleterious effect, neutrophils may also
exert neuroprotective functions as recently suggested (Cuartero
et al., 2013). In this study it was shown that in a mouse
model of permanent focal ischemia the neuroprotective effect
of the PPARγ agonist rosiglitazone was abolished in neutrophil
depleted animals. Rosiglitazone treatment induced an increase
of total number of neutrophils 24 h after ischemia and a shift
in the ratio of pro-inflammatory N1 neutrophils to N2 neu-
trophils shown by increased expression of the M2-marker pro-
tein Ym1 (Chil3). N2 neutrophils were recently defined as a
population of polarized cells with anti-inflammatory pheno-
type, in accordance to the M1/M2 classification of macrophages,
and have been found in tumors where they facilitate tumor
growth by inhibiting anti-tumor T cell responses (Fridlender
et al., 2009; Mantovani, 2009). Their role in brain ischemia,
including the mechanism of neuroprotection, remains to be
firmly established, but, analogous to the double-edged role
of monocytes/macrophages, neutrophils could also have ben-
eficial effects, perhaps in the repair phase of the injury.
For example, neutrophils that undergo apoptosis are ingested
by microglia and macrophages, which induce these phago-
cytic cells to become anti-inflammatory or promote tissue
repair (Serhan and Savill, 2005). Therefore, manipulating the
polarization state of neutrophils could also have therapeutic
relevance.
MONOCYTES AND MICROGLIA IN CEREBRAL ISCHEMIA
Under normal conditions, resident microglia are ramified,
have long processes and can be morphologically discerned
from macrophages (Nimmerjahn et al., 2005; Boche et al.,
2013). Resident microglia can be distinguished from BM-
derived monocytes according to their level of CD45 expres-
sion: microglia are CD11b+ and express intermediate level of
CD45 (CD11b+/CD45int), whereas monocytes are also positive
for CD11b but express high level of CD45 (CD11b+/CD45high)
(Ford et al., 1995). Monocytes can be further classified as Ly6Chigh
pro-inflammatory monocytes or Ly6Clow anti-inflammatory
monocytes (David and Kroner, 2011). Upon injury, microglia
adopt ameboid morphology and become phagocytic. Activated
microglia are commonly identified by the cellular markers: IB4,
Iba1, F4/80 or ED-1 (CD68). After cerebral ischemia, microglia
display different markers and morphology depending on their
localization in the ischemic territory and the course of reper-
fusion. In the ischemic core microglia have an ameboid shape,
are Iba1 positive and ED1 positive and have increased CD11b
expression, whereas in the peri-infarct area these cells have
shorter processes than in the resting state, are Iba1+, but are
negative for ED1 (Ito et al., 2001; Morrison and Filosa, 2013).
Once microglia differentiate into macrophages they share sev-
eral antigens and morphological features with hematogenous
macrophages (Patel et al., 2013), confounding the interpre-
tation of their origin and ultimately their function in acute
cerebral ischemia (Hanisch and Kettenmann, 2007; Hellwig et al.,
2013).
Several recent studies have attempted to distinguish microglia
from blood-derived macrophages and to define their role in
ischemic injury and repair, potentially opening novel therapeutic
avenues for the treatment of stroke. To this end, several strate-
gies have been used (Prinz and Priller, 2014). A widely used
approach has been to perform BM transplants with fluorescent
BM (Tanaka et al., 2003). One drawback to this approach is
that whole body irradiation may affect the integrity of the BBB
and induce brain cytokine production, creating a permissive
environment for brain engraftment of BM-derived immune cells
normally not found in the CNS (Mildner et al., 2007). Although
head shielding during irradiation or parabiosis may avoid such
disturbances, the resulting degree of chimerism (40–50%) is
not as high as with whole body irradiation (>90%) (Ginhoux
et al., 2013; Prinz and Priller, 2014). The reduced chimerism
obtained with these models may not be problematic for cell
tracking and fate determination experiments, but it will con-
found the interpretation of mechanistic studies on the relative
contribution of resident and blood-borne immune cells to tissue
damage and repair. Recently, it has been shown that chemi-
cal BM ablation with busulfan leads to a better rate of blood
chimerism with reduced inflammation and myeloid immune
cell recruitment in the mouse CNS compared to irradiation
(Kierdorf et al., 2013b). However, in our own experience, doses
of busulfan that produce a chimerism comparable to irradiation
lead to a myeloid immune cell recruitment in brain greater
than that seen with irradiation (Sugiyama et al., 2014). There-
fore, chemical BM ablation-based approaches require further
scrutiny.
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Another approach to track blood-borne myeloid cell infil-
tration into the ischemic area, has been to use ultrasmall
superparamagnetic iron oxide particles (USPIO), which labels
peripheral phagocytic cells after intravenous injection. USPIO
were delivered in one case 5.5 h after permanent MCA occlusion
(Rausch et al., 2001) and in an other study 24 h before inducing
photothrombotic strokes (Kleinschnitz et al., 2003). Brains were
analyzed at different time points after ischemia by magnetic
resonance imaging (MRI) and histology. While the temporal
profile was slightly different between the two studies, iron par-
ticles were detected late in the post-ischemic period, after most
of the damage had occurred (Rausch et al., 2001; Kleinschnitz
et al., 2003). In a model of neonatal ischemia, microglia—
identified as CD11b+/CD45low/int by flow cytometry—were the
predominant cell population in the infarct area compared to
CD11b+/CD45high monocytes (Denker et al., 2007). A simi-
lar pattern was described using GFP-BM chimeric mice. Thus,
Schilling et al. found that microglia were the first cells to be acti-
vated in the infarcted area, exhibited a more pronounced phago-
cytic activity and out-numbered GFP-BM monocytes (Schilling
et al., 2003, 2005). Collectively, these observations suggest that
microglia are likely to be the first cells activated after brain
injury, aiming at clearing the cell debris by phagocytosis and
contributing to the resolution of inflammation (Neumann et al.,
2009). On the other hand, phagocytosis could also contribute
to neuronal cell loss after ischemia. For example, it has been
suggested that microglia could engulf viable neurons in the
ischemic penumbra (Neher et al., 2013). Salvageable neurons
would send “eat me” signals to nearby microglia and induce
their phagocytosis that further increases brain damage (Neher
et al., 2012). In support of this hypothesis, deficiency of the
phagocytosis-related receptors Mertk and milk fat globule-EGF
factor 8 protein (Mfge8) on microglia promotes functional
recovery and reduces brain atrophy in focal infarcts (Neher
et al., 2013). On the other hand, deletion of triggering receptor
expressed on myeloid cells 2 (TREM2), a receptor expressed on
phagocytic microglia and macrophages, did not affect infarct
size in a focal ischemia model in mice (Sieber et al., 2013),
although TREM2 is essential for their phagocytosis capacity
(Takahashi et al., 2007). The molecular mechanisms regulating
these microglial behaviors need to be established and may provide
new insights into endogenous brain processes regulating injury
and repair.
CCR2+ MONOCYTES IN CEREBRAL ISCHEMIA
Recruitment of circulating monocytes to the ischemic brain
is orchestrated by inflammatory cytokines, de novo-expressed
adhesion molecules and chemokines. The monocyte chemoat-
tractant protein (MCP-1, CCL2) and its receptor CCR2 are
known to be involved in the inflammatory response of the
injured brain after cerebral ischemia (Che et al., 2001; Chu
et al., 2014a). After permanent and transient focal ischemia,
Gliem et al. found an increase in Ly6Chigh monocytes at 3 days,
whereas the number of Ly6Clow monocytes was greatest at 6 days,
paralleled by sequential peaks of CCR2 and CX3CR1 mRNA
as well as gene expression of the pro- and anti-inflammatory
cytokines IL-1β and TGF-β, respectively (Gliem et al., 2012).
Furthermore, they demonstrated that selective deletion of
CCR2 in BM-derived cells induced a delayed clinical deterio-
ration and hemorrhagic conversion of ischemic infarcts, sug-
gesting a beneficial role of CCR2+ monocytes in maintaining
the structure of the neurovascular unit (Gliem et al., 2012).
Because CCR2+/Ly6Chigh monocytes can transform into anti-
inflammatory Ly6ClowF4/80high macrophages, it was suggested
that lack of infiltrating CCR2+ monocytes results in reduction
of anti-inflammatory macrophages at later time points com-
promising repair mechanisms. However, several other studies
demonstrated reduced phagocytic macrophage accumulation in
the brain of CCL2 or CCR2 knock-out mice together with
smaller infarcts after cerebral artery occlusion (Hughes et al.,
2002; Dimitrijevic et al., 2007; Schilling et al., 2009), suggesting
a deleterious role of CCR2 monocytes. These discrepancies may
reflect the multifunctional roles of CCR2+ monocytes, which,
while contributing to early brain injury may also enable delayed
repair processes.
CX3CR1+ MONOCYTES AND MICROGLIA IN CEREBRAL ISCHEMIA
The chemokine CX3CL1 is found on neurons while its recep-
tor CX3CR1 is expressed on microglia and Ly6Clow mono-
cytes (Geissmann et al., 2003; Sunnemark et al., 2005; Limatola
and Ransohoff, 2014). CX3CR1−/− or CX3CL1−/− mice show
reduced brain damage in transient focal ischemia models com-
pared to wild type mice (Soriano et al., 2002; Dénes et al.,
2008; Fumagalli et al., 2013), although the effect might not be
sustained in time (Gliem et al., 2012). Neuroprotection found
in CX3CR1−/− mice following focal cerebral ischemia was cor-
related with an increase of the M2 macrophage marker genes
CD206 and Ym1 and a decrease of M1-iNOS gene expres-
sion compared to wild type mice (Fumagalli et al., 2013; Tang
et al., 2014). These findings indicate that CX3CR1 deficient mice
induce a different pattern of M1/M2 marker expression in the
ischemic region. The authors suggest that the lack of CX3CR1 in
microglia and infiltrated monocytes favors an anti-inflammatory
milieu that protects the brain from infarct development. How-
ever, intracerebroventricular delivery of CX3CL1 at the time of
MCA occlusion decreased infarct volumes (Cipriani et al., 2011),
suggesting that CX3CL1 acts on microglia to reduce their acti-
vation state and inhibit the release of inflammatory cytokines
(Zujovic et al., 2000; Cardona et al., 2006; Biber et al., 2007).
Michaud et al. has recently shown that selective ablation of
Ly6Clow/CX3CR1+ monocytes, thought to preferentially develop
into M2 macrophages, does not influence stroke outcome in a
hypoxic-ischemic injury model (Michaud et al., 2014). Using
NR4A1−/− BM chimeras that lack circulating Ly6Clow/CX3CR1+
monocytes (Carlin et al., 2013), it was found that structural
and functional outcome were not affected. However, brain infil-
trating monocytes have not been assessed in this study, and it
remains an open question whether Ly6Chigh/CCR2+ monocytes
in the brain parenchyma could give rise to Ly6Clow/CX3CR1+
monocytes/macrophages, even in the absence of the NR4A1
transcription factor.
Using parabiosis of CX3CR1GFP/+ mice and wild type part-
ners, Li et al. found that microglia increased gradually dur-
ing the first week after photothrombotic stroke (Li et al.,
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2013). Hypertrophic ameboid microglia were more abundant
in the periphery compared to the core of the lesion and many
GFP-positive microglia were labeled with the mitotic marker
bromodeoxyuridine (Li et al., 2013). In the wild type para-
biotic partner, CX3CR1GFP/+ infiltrating cells started to popu-
late the brain 5 days after ischemia onset, were less numerous
than activated microglia and did not proliferate, suggesting that
microglia and monocyte-derived CX3CR1 macrophages are two
distinct populations with presumably different roles in cerebral
ischemia.
M1 AND M2 PHENOTYPES IN CEREBRAL ISCHEMIA
Recent studies have begun to investigate microglia and
macrophage polarization in vivo. In a model of permanent
focal ischemia, different cell markers were used to characterize
the prevalence of phagocytic cells and M2-like phenotype at
different time after ischemia (Perego et al., 2011). Soon after
injury, ED-1 positive phagocytic cells were present at the border—
possibly limiting the expansion of the infarct—whereas Ym1-
and CD206-expressing cells were found in the ischemic core. At
7 days, more phagocytic cells invaded the ischemic core where
they engulfed neurons. In transient focal ischemia, M2-type gene
expression (CD206, Arg1, CCL22, Ym1/2, IL-10, and TGF-β) was
first apparent from 1 to 3 days after ischemia, peaked at 3–5 days,
was reduced at 7 days and returned to pre-injury levels by day
14. M1-type genes (iNOS, CD11b, CD16, CD32, and CD86) were
gradually increased from day 3 and remained elevated for 14 days
after ischemia (Hu et al., 2012). The M1/M2 phenotype was also
assessed in in vitro models of ischemic injury using microglia
and neuronal co-culture. M1-polarized microglia/macrophages
exacerbate neuronal death compared with M2 cells (Hu et al.,
2012; Girard et al., 2013). Hu et al. suggested that early expression
of M2 genes may contribute to neuroprotection by enhancing the
phagocytosis of dead cells, removal of tissue debris and promote
recovery. At later stages, cells displaying a M1 phenotype may
induce pro-inflammatory mediators and exacerbate neuronal
death. Therefore, limiting such M2 to M1 shift and promoting M2
polarization could be a potential therapeutic strategy (Hu et al.,
2012). In vitro experiments have to be interpreted with caution
because microglia are commonly derived from neonatal tissue
and develop in a culture environment that cannot recapitulate
the maturation process that occurs in vivo (Hellwig et al., 2013).
Importantly, the gene expression signature characteristic for adult
brain microglia is lost in primary neonatal microglia cultures
as well as in microglial cell lines including BV2 and N9 cells
(Butovsky et al., 2014). Thus, in vivo translation of findings
obtained with in vitro polarization models might not be easily
achieved. Desestret et al. administered differentiated BM-derived
M2 macrophages 4 days after cerebral ischemia by intravenous
injection. M2 macrophages failed to induce protection or
improve behavioral outcome (Desestret et al., 2013). On the
other hand, Girard et al. have proposed that M1 and M2
BM-derived macrophages promote cell death in vitro, whereas
M2 microglia is neuroprotective. However, microglia does not
display a classic M1 and M2 phenotypes after MCA occlusion
(Girard et al., 2013). The ability of microglia to differentiate into
multiple macrophage-related phenotypes depending on their
microenvironment highlights the complexity of their response to
cerebral ischemia (Taylor and Sansing, 2013).
A ROLE FOR SPLENIC MONOCYTES IN BRAIN ISCHEMIA?
The discovery of a splenic monocyte reservoir in adult mice, that
is mobilized following ischemic myocardial injury (Swirski et al.,
2009), has sparked renewed interest in the role of the spleen
in brain ischemia. Previous studies have shown that splenocytes
respond to cerebral ischemia by producing large amounts of
inflammatory mediators early after injury (Offner et al., 2006b),
followed later by an increase of blood monocytes and splenic
regulatory T cells, that are thought to dampen the inflammatory
response (Offner et al., 2006a). In accordance with these findings,
chronic splenectomy (Ajmo et al., 2008) or acute spleen irradia-
tion (Ostrowski et al., 2012) have been performed in rats to inhibit
systemic inflammatory responses after stroke. Although the stud-
ies differed in the ischemic model, i.e., permanent vs. tran-
sient ischemia, both studies observed neuroprotection together
with a decrease of immune cell counts in the ischemic region.
In addition, post-stroke treatment with the antibacterial agent
moxifloxacin (MFX) reduced peripheral infection and infarct
size in animal models of stroke (Meisel et al., 2004; Bao et al.,
2010). In MFX-treated mice the percentage of the splenic pro-
inflammatory Ly6Chigh monocytes was reduced compared to
vehicle animals 7 days after stroke, together with reduced expres-
sion of CCR2 in the spleen and the brain (Bao et al., 2010). These
studies suggest that interventions aiming at reducing systemic
inflammation, specifically by targeting splenocytes, could lead to a
reduction of brain immune cell infiltration and neuroprotection.
However, these reports did not assess whether leukocytes, specifi-
cally monocytes, found in the brain originate from the spleen and
contribute directly to stroke outcome. For instance, Ajmo et al.
did not find alteration of immune cell counts in peripheral blood
following MCA occlusion in sham or splenectomized animals,
while spleen irradiation after MCA occlusion resulted in a drop
of circulating lymphocytes, but failed to lower blood monocytes
and neutrophils (Ajmo et al., 2008; Ostrowski et al., 2012). Thus
it is not clear whether peripheral immune cells are mobilized
from the spleen into the brain and contribute directly to stroke
outcome. Recently, Kim et al. analyzed the temporal profile of
brain infiltrating Ly6Chigh and Ly6Clow monocytes after focal
ischemic injury in acutely splenectomized mice (Kim et al., 2014).
In sham mice, they found that brain ischemia induced a reduction
of both monocytes subsets in the spleen that temporally correlated
with their increase in the ischemic brain. In splenectomized
mice, brain Ly6Chigh and Ly6Clow monocytes were reduced at
1 and 3 days after stroke compared to sham surgery. However
no difference in infarct size was observed between groups (Kim
et al., 2014). While this study did not directly track splenic
monocytes and the findings remain correlative, it suggests that the
spleen might contribute both Ly6Chigh and Ly6Clow monocytes
after brain ischemia. The failure to observe neuroprotection in
this model might be related to simultaneous reduction of both
monocyte subsets, thus balancing the loss of deleterious Ly6Chigh
monocytes with the loss of beneficial Ly6Clow monocytes, which
might be involved in resolution of the inflammation and tissue
repair (Shechter et al., 2013).
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MYELOID IMMUNE CELLS IN HUMAN STROKE
TEMPORAL PROFILE OF MYELOID IMMUNE CELL ACTIVATION AND
INFILTRATION
Histological analysis of autopsy material from patients allowed
to draw a temporal profile of cellular events from 1 day after
stroke onset to several years (Chuaqui and Tapia, 1993; Mena
et al., 2004). Astrogliosis was observed within the first day of
cerebral infarct development together with neutrophils, which
were observed in 81% of cases between 3–37 days after stroke
onset (Mena et al., 2004). This active inflammatory phase was
accompanied by tissue necrosis and infiltration of inflammatory
cells such as mononuclear cells and macrophages, which were not
observed during the first 2 days after stroke onset. Interestingly,
inflammatory mononuclear cells and macrophages persisted up
to 53 years and were found in the majority of late stage specimens
while neutrophils were absent (Mena et al., 2004). Although the
temporal sequence and type of cells in the infarct are similar in
rodents and humans (Gelderblom et al., 2009), the chronology of
events seems to be more delayed and more spread out in time in
humans.
Advanced imaging techniques to visualize post-ischemic
inflammation and leukocyte infiltration are increasingly being
employed in the clinical setting. Visualization of infiltrated
macrophages in stroke patients was performed by USPIO-MRI
(Saleh et al., 2004, 2007; Cho et al., 2007). In all patients tested,
an increase signal of USPIO was observed by MRI in the brain
parenchyma (Saleh et al., 2004). Only a minority of patients that
received USPIO between 24 h and 96 h after symptom onset
showed a positive signal in the brain (Cho et al., 2007; Saleh et al.,
2007). However, iron-positive cells detected in the brain cannot
represent only monocytes since activated microglia can engulf
iron particles as well (Oude Engberink et al., 2008; Desestret et al.,
2009). Injection of iron oxide monocytes labeled ex vivo allowed
to follow their brain infiltration in experimental models of stroke
(see previous section) (Stroh et al., 2006; Oude Engberink et al.,
2008). Similarly, the use of ex vivo monocyte labeling in humans
may increase our understanding of the temporal pattern of blood-
borne cell infiltration after stroke. Positron emission tomography
(PET) has been used to label inflammatory cells in stroke patients
using the radioligands 11C(R)-PK11195 for the translocator pro-
tein 18kDa (TSPO), commonly used as a microglial marker
(Stephenson et al., 1995; Cagnin et al., 2007). Analysis in patients
showed an increase of the marker between 3 and 150 days after
stroke (Gerhard et al., 2005). Positive labeling was observed early
after ischemia, initially at the periphery of the lesion, then in the
infarct core and eventually in peri-infarct regions (Gerhard et al.,
2005; Thiel and Heiss, 2011). Altogether, the time of magnetic
particles or radiolabelled agents infusion might be critical to
discriminate resident microglia from immune cells of myeloid
origin (Deddens et al., 2012). However, a limitation is that these
techniques of brain macrophage visualization do not permit to
differentiate between their different subtypes and activation states
(Weissleder et al., 2014).
MONOCYTE SUBSETS IN PATIENTS WITH CEREBRAL ISCHEMIA
In human three distinct blood monocytes can be distinguished
relative to the expression of the receptor CD14 (LPS co-receptor)
and CD16 (Fcγ receptor III). The majority of human “clas-
sical” monocytes express high level of CD14 and are nega-
tive for CD16 (CD14++/CD16−), whereas the minor subtypes
express CD16 and can be either CD14high (CD14++/CD16+)
or CD14low (CD14dim/CD16+), also known as intermediate
and non-classical monocytes, respectively (Ziegler-Heitbrock,
1996; Ziegler-Heitbrock et al., 2010). The classical monocytes
CD14+/CD16− share some features with the murine Ly6Chigh
monocytes such as the high expression of the chemokine receptor
CCR2 (Weber et al., 2000), whereas CD16+ cells express CX3CR1
similar to mouse Ly6Clow monocytes (Merino et al., 2011). How-
ever, the pro- or anti-inflammatory functions of these different
monocyte subsets depend on the inflammatory context and, as
in the mouse, a strict association of phenotype and function can
not be established (Gordon and Taylor, 2005; Ziegler-Heitbrock,
2007; Merino et al., 2011). For example, blood monocyte subsets
from healthy donors showed different pattern of response when
stimulated with LPS (Frankenberger et al., 1996; Skrzeczyn´ska-
Moncznik et al., 2008). CD14dim/CD16+ monocytes were found
to produce more TNF compared to CD14high/CD16+ and
CD14high/CD16− monocytes, whereas CD14high/CD16+ were the
main source for IL-10, (Belge et al., 2002; Skrzeczyn´ska-Moncznik
et al., 2008).
Similar to the mouse (Offner et al., 2006b), stroke has a signifi-
cant impact on the peripheral immune system in humans (Kamel
and Iadecola, 2012). Although there is significant immunosup-
pression in acute stroke (Meisel et al., 2005; Chamorro et al.,
2006), a significant increase of circulating monocytes has also
been reported (Losy and Zaremba, 2001). The different sub-
types of blood monocytes were investigated in patients following
stroke and were correlated with outcome severity (Urra et al.,
2009). The CD14high/CD16+ subset was increased 48 h after
admission, while a parallel decrease in the CD14dim/CD16+
subtype was observed. An increase in classical CD14high/CD16−
monocytes was associated with poor outcome, whereas increased
CD16+ monocytes were linked to a better prognosis (Urra et al.,
2009). CD14 expressing cells were observed in brain tissue from
patients with focal infarction as early as 1 day and persisted for
months after ischemia (Beschorner et al., 2002), suggesting a
long-term involvement in inflammatory processes at the site of
injury.
There is still a large knowledge gap about human microglia
and immune cells of myeloid origin regarding their activation
state, spatiotemporal distribution in the brain and, ultimately,
about their role in acute cerebral ischemia. Advanced brain imag-
ing modalities in humans and new cerebral ischemic models
more representative of human stroke would help enhance our
understanding of the inflammatory processes occurring in acute
cerebral ischemia and to test therapeutic strategies directed at
manipulating their beneficial or deleterious effects.
TARGETING INFLAMMATION AS THERAPEUTIC STRATEGIES
The only successful treatment for ischemic stroke is thrombol-
ysis with tissue plasminogen activator (tPA), which, due to the
narrow therapeutic window (<4.5 h) (Hacke et al., 2008) and
safety concerns, is administered to less than 5% of patients
(Fonarow et al., 2011). Different strategies aimed at preventing
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the inflammatory response after cerebral ischemia have been
successful in rodent models. Ischemic damage was shown to be
attenuated, among others, by inhibition of microglial activation
using the immunomodulatory antibiotic minocycline, systemic T
lymphocytes depletion using sphingosine 1-phosphate receptor
agonist (FTY720), diminishing free radical generating and pro-
inflammatory enzymes, such as iNOS or cyclooxygenase-2, inhi-
bition of cytokines secretion, or targeting adhesion molecules (for
reviews, Dirnagl et al., 1999; Iadecola and Alexander, 2001; Wang,
2005; Jordán et al., 2008).
Unfortunately attempts to translate anti-inflammatory thera-
peutic interventions into the clinics have been more disappointing
than promising (O’Collins et al., 2006; Moskowitz et al., 2010).
The selective IL-1 receptor antagonist, IL1-ra, which limits the
pro-inflammatory action of IL-1, has been tested in random-
ized patients with acute stroke (Emsley et al., 2005). Despite a
conclusive phase II study no recent publications have reported
the recombinant human IL1-ra as a therapeutic agent for acute
stroke. Strategies to inhibit neutrophil infiltration have been
tested in clinical trials. Treatment with the murine mono-clonal
anti-ICAM-1 in the Enlimomab trial (Enlimomab Acute Stroke
Trial Investigators, 2001) or UK-279,276 (neutrophil inhibitory
factor) have failed to improve recovery in acute ischemic stroke
patients (Krams et al., 2003). Likewise, NXY-059, a nitrone-based
free radical trapping agent, has not demonstrated any benefits in
stroke clinical trials (Shuaib et al., 2007). The granulocyte colony-
stimulating factor (G-CSF), that stimulates proliferation, survival,
and maturation of BM-derived cells, has shown neuroprotective
effect in models of transient focal ischemia by inducing mobi-
lization of haemopoietic stem cells, by having anti-apoptotic and
anti-inflammatory properties, as well as by promoting neuronal
differentiation and angiogenesis (Komine-Kobayashi et al., 2006;
England et al., 2009). However, recent results from a large phase
IIb trial (AXIS-2) was not able to detect clinical efficacy in acute
ischemic stroke patients (Ringelstein et al., 2013).
Reasons for failure have been discussed extensively in the
literature and might include ambivalent roles of post-stroke
inflammation as well as functional differences between rodent
and human immune systems, patient inclusion criteria, timing of
intervention, evaluation of efficacy, pharmacokinetic issues and
side effects such as promoting infections and fever (for review,
Dirnagl, 2006; Endres et al., 2008). Before translating experimen-
tal findings into therapies that target the immune system in stroke
patients, there is a need to better understand the spatiotemporal
profile and functional states of immune cells involved in ischemic
brain injury in humans. A better insight in these aspects is
crucial for planning future clinical trials targeting post-ischemic
inflammation.
CONCLUDING REMARKS
The surprising plasticity of myeloid immune cells and microglia
in their response to tissue injury highlights the need for further
research to define spatiotemporal profiles of their distinct subsets
in ischemic brain injury. Given the neuroprotective potential
of some of these subsets, it has become clear that inhibiting
inflammation in general or indiscriminately blocking leukocyte
access to the brain might not be a viable therapeutic approach.
The failure of clinical trials that targeted post-ischemic leukocyte
recruitment might be in part explained by the indiscriminate
nature of these approaches and a lack of a nuanced understanding
of the impact of inflammation on damage and repair processes
in the post-ischemic brain. Our understanding of the behavior
of myeloid immune cells and microglia in ischemic stroke is still
limited. Key questions to be addressed in future research include
the transcriptomic and proteomic characterization of myeloid
immune cell subsets at different stages of brain ischemia, the
mechanism of monocytes, neutrophils and microglia polariza-
tion in the ischemic environment, and the neural and humoral
signals generated by the ischemic brain to modulate periph-
eral immune cell activation and mobilization. Answering some
of these questions would provide the knowledge base needed
to design more specific immunotherapies for the treatment of
ischemic stroke.
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